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DOI 10.1016/j.ccr.2011.11.023SUMMARYCurrent strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer
patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal
tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this
concept, a study was performed in non-small cell lung cancer (NSCLC) patients using positron emission
tomography (PET) and radiolabeled docetaxel ([11C]docetaxel). In NSCLC, bevacizumab reduced both
perfusion and net influx rate of [11C]docetaxel within 5 hr. These effects persisted after 4 days. The clinical
relevance of these findings is notable, as there was no evidence for a substantial improvement in drug
delivery to tumors. These findings highlight the importance of drug scheduling and advocate further studies
to optimize scheduling of anti-angiogenic drugs.INTRODUCTION
Angiogenesis is a critical component for growth and metastatic
spread of tumors (Hanahan and Weinberg, 2000; Carmeliet,
2000). Vascular endothelial growth factor (VEGF), which is over-
expressed in many human malignancies, is a key regulator of
tumor angiogenesis, inducing proliferation, differentiation, and
migration of endothelial cells (Ferrara et al., 2003). Consequently,
numerous drugs have been developed to target the signaling
pathways of VEGF and its receptors (VEGFR; Ferrara andKerbel,
2005).
Bevacizumab is a humanized monoclonal antibody that
targets circulating VEGF and subsequently prevents binding of
VEGF to its receptors (Ferrara et al., 2004). Except for metastaticSignificance
Optimal scheduling of anti-angiogenic drugs is important for
advanced-stage cancer. In this study, effects of the anti-ang
non-small cell lung cancer (NSCLC) were investigated using
Bevacizumab induced a rapid and significant reduction in deliv
provides a framework for investigating effects of anti-angiogen
lights the importance of drug scheduling and advocates furthe
82 Cancer Cell 21, 82–91, January 17, 2012 ª2012 Elsevier Inc.renal cell cancer (Yang et al., 2003), clinical efficacy of single-
agent bevacizumab treatment has been very limited in the
majority of advanced malignancies (Reese et al., 2001; Cobleigh
et al., 2003). Combined with chemotherapy, however, additional
value was shown in colorectal (Hurwitz et al., 2004), breast (Miller
et al., 2007), and non-small cell lung cancer (NSCLC; Sandler
et al., 2006).
In the past years, the normalization theory proposed by Jain
(2001) has gained widespread acceptance for explaining
additional antitumor effects of inhibitors of VEGF signaling,
when combined with cytotoxic drugs. It is hypothesized that
anti-angiogenic drugs normalize structurally and functionally
abnormal tumor vasculature, thereby reducing interstitial fluid
pressure, improving drug penetration, and subsequentlyimproving efficacy of combination therapy in patients with
iogenic drug bevacizumab on delivery of chemotherapy to
positron emission tomography and 11C-labeled docetaxel.
ery of chemotherapy to tumors in NSCLC patients. The study
ic drugs on drug delivery to tumors in vivo. In addition, it high-
r studies to optimize scheduling of anti-angiogenic drugs.
Figure 1. Tumor Measurements in 10 NSCLC
Patients at Baseline and after Administration of
Bevacizumab
Horizontal bars represent median values.
(A) Perfusion (F).
(B) Volume of distribution of water (VT).
(C) F/VT.
(D) Net rate of influx (Ki) of [
11C]docetaxel.
*p value < 0.05; **p value < 0.01.
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normalization window may be crucial for optimizing drug
scheduling in order to improve clinical efficacy. To date,
however, no clinical studies have been reported on the effects
of anti-angiogenic agents on drug delivery in cancer patients.
Positron emission tomography (PET) is a noninvasive imaging
technique that can be used to monitor drug pharmacokinetics
and pharmacodynamics in vivo by radiolabeling drugs of interest
with short-lived positron emitting radionuclides (Gambhir, 2002).
Previously, the cytotoxic drug docetaxel, a taxane targeting the
microtubular network, has been radiolabeled with the radionu-
clide C-11 ([11C]docetaxel; van Tilburg et al., 2004), enabling
in vivo quantification of docetaxel kinetics in lung cancer (Van
der Veldt et al., 2011). In the latter study, feasibility of noninvasive
PET measurements using radiolabeled water ([15O]H2O) and
[11C]docetaxel was demonstrated and uptake of [11C]docetaxel
in lung tumors was found to be associated with tumor perfusion,
measured using [15O]H2O.
The purpose of the present study was to investigate the
effects of anti-angiogenic drugs on tumor perfusion and
[11C]docetaxel delivery in patients with advanced-stage NSCLC
using PET. To this end, bevacizumab was selected, as it is the
most selective inhibitor of VEGF signaling among currently
approved anti-angiogenic drugs. It was hypothesized that
bevacizumab improves drug delivery by normalizing tumor
vasculature, which should be reflected by a more homogeneous
distribution of perfusion and [11C]docetaxel delivery. A
secondary objective of this study was to investigate (systemic)
effects of bevacizumab on (1) circulating VEGF levels in plasma;
(2) cardiovascular parameters, including blood pressure,
cardiac output, and microcirculation in muscle and skin; (3)
systemic exposure of [11C]docetaxel; and (4) perfusion and
[11C]docetaxel uptake in normal tissues. For the latter, the
thyroid gland and the vertebral body were selected. The thyroid
gland is known to be highly sensitive to VEGF inhibition (Kamba
et al., 2006), whereas the vertebral body may reflect effects of
bevacizumab on [11C]docetaxel uptake in bone marrow.Cancer Cell 21RESULTS
Bevacizumab Induces Rapid Reduction
in Tumor Perfusion
To investigate the effect of anti-VEGF therapy
on tumor perfusion (F), PET scans using
[15O]H2O, which is a freely diffusible tracer
(Hoekstra et al., 2002; Wilson et al., 1992),
were performed at baseline and 2 hr, 5 hr, and
4 days after bevacizumab administration. Five
hours after bevacizumab administration, therewas a significant reduction in tumor perfusion, which persisted
until day 4 (Figures 1A and 2A). In three out of eight patients,
tumor perfusion already decreased 2 hr after the end of bevaci-
zumab infusion. Accordingly, tumor perfusion showed median
percentage changes of 8% (range39 to +15%; N = 9; p value =
0.889), 20% (range, 39 to 7%; N = 8; p value = 0.012),
and 38% (range, 55 to 4%; N = 10; p value = 0.005) at
2 hr, 5 hr, and 4 days after bevacizumab administration, respec-
tively. In addition, the volume of distribution of water (VT),
a measure of the (viable) fraction of tissue that is able to
exchange [15O]H2O, was decreased at 4 days after bevacizumab
administration (Figure 1B), with a median percentage change
of 7% (range, 52 to +2%; N = 10; p value = 0.022). Individu-
ally, eight out of ten patients showed a reduction in volume of
distribution of water. Although both perfusion and volume of
distribution of water showed an overall decrease, the reduction
in perfusion was more severe, as illustrated by a significant
decrease in the ratio of tumor perfusion over volume of distribu-
tion (F/VT; (Figure 1C). Collectively, these findings indicate that
the decrease in tumor perfusion is not due to a reduction in
tumor tissue, which was confirmed by an unchanged tumor
volume on subsequent computed tomography (CT) scans.
Bevacizumab Decreases the Net Influx Rate of
[11C]docetaxel in Tumors
To determine whether delivery of chemotherapy is affected by
bevacizumab, PET scans using [11C]docetaxel were performed
at baseline and 5 hr and 4 days after bevacizumab administra-
tion. Kinetics of [11C]docetaxel in tumor tissue are irreversible
and can be quantified using Patlak graphical analysis, providing
the net influx rate constant (Ki) of [
11C]docetaxel in tumor
tissue (Patlak et al., 1983; Van der Veldt et al., 2011). Prior
to bevacizumab infusion, tumors showed a variable Ki of
[11C]docetaxel (median Ki, 0.0132 ml$cm
3$min1; range,
0.0054–0.0247 ml$cm3$min1; N = 10). After administration of
bevacizumab, median Ki of [
11C]docetaxel significantly
decreased (Figures 1D and 2B), resulting in amedian percentage, 82–91, January 17, 2012 ª2012 Elsevier Inc. 83
Figure 2. PET-CT Images of a 51-Year-Old Woman
with Metastatic Non-Small Cell Lung Cancer
(A) Parametric perfusion images obtained at baseline
and at 5 hr and 4 days after bevacizumab administration.
In the whole tumor, the mean perfusion changed from
0.875ml$cm3$min1 at baseline to 0.765ml$cm3$min1
at 5 hr and 0.535 ml$cm3$min1 at 4 days.
(B) Patlak images of [11C]docetaxel uptake obtained at
baseline and at 5 hr and 4 days after bevacizumab
administration. In the whole tumor, the mean Ki of
[11C]docetaxel changed from 0.0205 ml$cm3$min1 at
baseline to 0.0193 ml$cm3$min1 at 5 hr and
0.0127 ml$cm3$min1 at 4 days.
F, perfusion; Ki, net influx rate constant.
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Effects of Bevacizumab on Delivery of Chemotherapychange of 22% (range, 51 to 4%; N = 9; p value = 0.008)
and 34% (range, 61 to 16%; N = 10; p value = 0.005) at
5 hr and 4 days, respectively. In line with the decrease in
the volume of distribution of water, the distribution volume of
[11C]docetaxel, which can be obtained from the Patlak plot,
also showed a decline on day 4 with a median percentage
change of 14% (range, 24 to + 20%; N = 10; p value =
0.052). Before administration of bevacizumab, [11C]docetaxel Ki
was associated with tumor perfusion (Spearman’s r = 0.626;
N = 10; p value = 0.053). As two patients had one missing scan
(either [11C]docetaxel PET or [15O]H2O PET), this correlation
could not be evaluated at 5 hr. At 4 days, the correlation between
[11C]docetaxel Ki and perfusion showed a slight decrease
(Spearman’s r 0.564; N = 10; p value = 0.090).
Tumor Heterogeneity of [11C]docetaxel Uptake
Is Not Affected by Bevacizumab
As it is assumed that normalization of tumor vasculature results
in a more homogenous distribution of perfusion and drug
delivery, spatial distributions of tumor perfusion, volume of
distribution of water, and [11C]docetaxel Ki were analyzed on
a voxel-by-voxel basis using histogram analysis. For the Ki of
[11C]docetaxel, only the median kurtosis of the histograms
showed a trend toward an increase from 2.60 at baseline to
3.11 (N = 9; p value = 0.051) and 2.97 (N = 10; p value = 0.059)
at 5 hr and 4 days, respectively, whereas standard deviation
and kurtosis of the other histograms (F and VT) did not change.
When histogram analysis was applied to separately analyze
tumor center and rim, larger tumors showed lower perfusion
and lower values of [11C]docetaxel Ki in the center than in the
rim. When all primary tumors were analyzed, median baseline
values, however, were not significantly different (N = 10; p value =
0.739 and 0.579, respectively). At 5 hr and 4 days after bevacizu-
mab administration, mean, median, minimum, and maximum
values of tumor perfusion and [11C]docetaxel Ki showed the
same degree of reduction (p value < 0.05) in the whole tumor,
as in the center and the rim separately. In addition, the volume
of distribution of water showed a significant decrease in both
center and rim at 4 days (N = 10; p value < 0.05). Standard devi-
ation and kurtosis of all histograms (F, VT, and [
11C]docetaxel Ki)
did not change in the center and the rim, except for a decreased
standard deviation of perfusion in the center at 5 hr (N = 8;
p value = 0.028). Furthermore, changes in perfusion, volume of84 Cancer Cell 21, 82–91, January 17, 2012 ª2012 Elsevier Inc.distribution of water, and [11C]docetaxel Ki were not associated
with baseline tumor volumes. Collectively, these results indicate
that bevacizumab induces an overall decrease in perfusion,
volume of distribution of water, and [11C]docetaxel Ki in tumors
without significantly affecting tumor heterogeneity.
Decrease in [11C]docetaxel Delivery to Tumors Is
Accompanied by Rapid Reduction in Circulating VEGF
Plasma levels of circulating VEGF were measured to evaluate
whether the rapid decrease in [11C]docetaxel Ki in tumors was
supported by a rapid decrease in free VEGF. As VEGF is mainly
transported by platelets (Verheul et al., 1997), circulating VEGF
was assessed in both platelet-poor and platelet-rich plasma.
At 3 hr, administration of bevacizumab resulted in a significant
decrease in circulating VEGF in platelet-rich plasma (N = 7;
p value = 0.018; Figure 3). In the majority of patients, free
VEGF in plasma was completely neutralized within 3 hr and
seemed to recover in part after 4 days. Comparable changes
in VEGF levels were measured in platelet-poor plasma.
A Reduction in [11C]docetaxel Delivery to Tumors Is Not
Associated with Cardiovascular Parameters
Because arterial hypertension and cardiotoxicity are commonly
reported side effects associated with inhibitors of VEGF/
VEGFR-2 signaling (Chen and Cleck, 2009), it was investigated
whether the rapid decrease in tumor perfusion and [11C]doce-
taxel Ki was accompanied by early onset cardiovascular
changes. A single infusion of bevacizumab did not affect systolic
and diastolic blood pressure during the first 4 days (Figures 4A
and 4B). Median cardiac output as derived from first pass
dynamic [15O]H2O PET scans (Knaapen et al., 2008), however,
showed a trend toward a reduction at day 4 (from 6.9 l$min1
to 6.0 l$min1; N = 9; p value = 0.051; Figure 4C). As inhibitors
of VEGF/VEGFR-2 signaling may induce so-called rarefaction
(Mourad et al., 2008), that is, a reduction in the number of arteri-
oles or capillaries within vascular beds of various tissues (e.g.,
muscle and skin), muscle perfusion in the erector spinae, as
well as capillary density in the skin, were measured. Muscle
perfusion was obtained from the [15O]H2O images, whereas nail-
fold capillaries in the dorsal skin of the third finger were examined
using a capillary microscope (Serne´ et al., 2001). Perfusion in the
erector spinae muscle and capillary density in the skin did not
change during the first 4 days after administration of
Figure 3. Platelet-rich Plasma Levels of VEGF in Seven Individual
Patients at Baseline and after Administration of Bevacizumab
Vascular endothelial growth factor levels were corrected for platelet count and
are expressed in pg$ml1 per 200,000 platelets$ml1. Horizontal bars represent
median values.
*p value < 0.05.
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in muscle tissue (median Ki, 0.0072 ml$cm
3$min1; range,
0.0029–0.0104 ml$cm3$min1) was lower than that in tumor
tissue (N = 10; p value = 0.002). The Ki of [
11C]docetaxel in
muscle tissue was neither associated with perfusion nor affected
by bevacizumab.
Bevacizumab Increases Systemic Exposure
of [11C]docetaxel
To investigate whether decreased [11C]docetaxel Ki in tumor
tissue was associated with a change in systemic exposure of
[11C]docetaxel, plasma clearance of [11C]docetaxel was deter-
mined. Four days after bevacizumab administration, plasma
clearance of [11C]docetaxel was significantly decreased (N = 10;
p value = 0.037), as reflected by a shift to the right of the plasma
curves (Figure 5). Consequently, bevacizumab increased thedura-
tionof [11C]docetaxel exposurebya reduction inplasmaclearance.
However, this increased systemic exposure of [11C]docetaxel did
not result in increased [11C]docetaxelaccumulation in tumor tissue,
as the retention index of [11C]docetaxel still decreased after
bevacizumabadministration (from0.0155ml$cm3$min1atbase-
line to 0.0109 ml$cm3$min1 at day 4; N = 10; p value = 0.005).
Bevacizumab Decreases Thyroid Perfusion
Because normal vessels of the thyroid gland are known for their
extensive capillary regression after anti-VEGF therapy (Kamba
et al., 2006), thyroid perfusion was also determined using para-
metric perfusion images. In four out of ten patients, the primary
tumorwas located in the upper lobes, enabling adequate analysis
of thyroid perfusion at baseline and day 4. Four days after beva-
cizumab administration, median perfusion in the thyroid gland
showed a decrease (from 1.316 ml$cm3$min1 at baseline to
0.585 ml$cm3$min1 at day 4; p value = 0.068), whereas the
volume of distribution of water did not change (p value = 0.273).
[11C]docetaxel Uptake in Bone Marrow Is Not Affected
by Bevacizumab
As [11C]docetaxel shows high uptake in bone marrow (Van der
Veldt et al., 2010b) and anti-VEGF therapy can block rapidinduction of viable circulating endothelial progenitor cells from
bone marrow and can inhibit taxane-induced bone marrow
colonization in tumors (Shaked et al., 2008), the effects of beva-
cizumab on [11C]docetaxel uptake in bone marrow was also
evaluated. To this end, perfusion and [11C]docetaxel Ki were
determined in the vertebral body. Perfusion values were signifi-
cantly lower in the vertebral body than in tumors (N = 10; p value=
0.003), whereas Ki values of [
11C]docetaxel were significantly
higher than those in tumors (N = 10; p value < 0.001; Figure 6).
In contrast to tumor tissue, there was no association between
[11C]docetaxel Ki and perfusion in the vertebral body (Spear-
man’s r = 0.285; N = 10; p value = 0.425). Perfusion and
[11C]docetaxel Ki did not change after bevacizumab administra-
tion (Figure 6).
DISCUSSION
Current strategies combining anti-angiogenic therapy with cyto-
toxic agents have shown proven efficacy in cancer patients,
including those with advanced-stage NSCLC (Sandler et al.,
2006). Pretreatment with anti-angiogenic drugs may transiently
normalize abnormal tumor vasculature (Batchelor et al., 2007)
and thereby contribute to improved delivery of subsequent
chemotherapy, enhancing efficacy (Jain, 2005). Investigating
this process of vasculature normalization in vivo is a major
challenge, which is mainly restricted to imaging studies.
Whereas conventional imaging studies, such as CT and mag-
netic resonance imaging, have concentrated on changes in
tumor perfusion, the present concept of PET imaging using a
radiolabeled drug to study drug delivery in patients after anti-
VEGF therapy has not been reported yet. The humanized mono-
clonal antibody bevacizumab induced an overall decrease in
both perfusion and Ki of [
11C]docetaxel in tumor tissue within
a few hours after bevacizumab administration, a decrease
that persisted for at least four days. These findings represent
physiological changes in tumors, as measured changes were
beyond the known test-retest variability (van der Veldt et al.,
2010a and 2011). The large range of changes in perfusion and
[11C]docetaxel uptake is most likely due to interpatient differ-
ences in tumor response to bevacizumab and partly due to
differences in interval between end of bevacizumab infusion
and PET scans. Nevertheless, the results indicate a decrease
in perfusion and [11C]docetaxel uptake in tumor tissue of all
patients. Based on these data, it can be concluded that anti-
VEGF therapy is not able to improve drug delivery to tumors
but rather has the opposite effect.
Results of the present study are at variance with those ob-
tained by Willett et al. (2004), where improved drug delivery in
rectal cancer was postulated partly based on human imaging
studies. Tumor perfusion, as determined by dynamic contrast-
enhanced CT scanning decreased, whereas the standardized
uptake value of 20-deoxy-20-[18F]fluoro-D-glucose ([18F]FDG)
remained unchanged at 12 days after bevacizumab administra-
tion. However, kinetics of [18F]FDG are fundamentally different
from those of anticancer drugs, as [18F]FDG reflects glucose
metabolism. In the present study, however, the decrease in
standard deviation of tumor perfusion in the center of the
tumor at 5 hr and the increase in kurtosis of [11C]docetaxel
histograms may reflect a more homogenous distribution asCancer Cell 21, 82–91, January 17, 2012 ª2012 Elsevier Inc. 85
Figure 4. Cardiovascular Variables in Ten NSCLC
Patients at Baseline and after Administration of
Bevacizumab
Horizontal bars represent median values.
(A) Systolic blood pressure (SBP).
(B) Diastolic blood pressure (DBP).
(C) Cardiac output.
(D) Perfusion (F) in muscle tissue.
(E) Nailfold capillary density.
(F) Nailfold capillary density during venous occlusion (VO).
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less, these possible changes in tumor heterogeneity did not
result in improved drug delivery, as bevacizumab infusion
caused a rapid and overall reduction in [11C]docetaxel Ki in
tumors. In addition, drug uptake may be further impaired by
development of tumor necrosis, associated with extensive
vascular damage, which usually develops after anti-VEGF
therapy. Although it is not possible to define necrotic areas on
low-dose CT, development of necrotic areas was possibly re-
flected by a reduction in the distribution volume of water after
4 days, despite an unchanged total tumor volume on low-dose
CT.
Apart from tumor parameters, systemic effects after admin-
istration of bevacizumab were evaluated. The rapid changes
in tumor perfusion and [11C]docetaxel Ki were associated with
an immediate reduction in plasma levels of VEGF, indicating
an immediate inhibition of VEGF signaling in the whole body.
This rapid neutralization of circulating VEGF also induced a
decrease in perfusion of the thyroid gland, whereas perfusion
and [11C]docetaxel Ki in the vertebral body and muscle tissue
were not affected. In addition, Ki values of [
11C]docetaxel in the
vertebral body and muscle tissue were essentially different
from that in tumor tissue and were not related to perfusion in
these normal tissues. These findings imply that tumor tissue
shows a difference in sensitivity to VEGF inhibition (Kamba
et al., 2006) and in drug delivery as compared with normal
tissues. Among the cardiovascular parameters, only cardiac
output showed a decrease at day 4, whereas blood pressure
and capillary density did not change during the first 4 days after86 Cancer Cell 21, 82–91, January 17, 2012 ª2012 Elsevier Inc.bevacizumab infusion. These findings indicate
that the rapid and significant changes in
perfusion and [11C]docetaxel Ki in tumors are
not caused by immediate development of
hypertension, microvascular rarefaction, or a
rapid reduction in cardiac output. Conse-
quently, it can be concluded that the decrease
in perfusion and [11C]docetaxel Ki in tumors
can be attributed to rapid inhibition of VEGF
signaling in tumors. As the decrease in perfu-
sion and [11C]docetaxel uptake in tumors is
probably too rapid to be solely ascribed to
inhibition of tumor angiogenesis, vasoconstric-
tive effects of anti-angiogenic drugs on tumor
vessels, particularly those from the host,
should be considered as a potential underlying
mechanism. In this regard, inhibition of endo-
thelial nitric oxide synthesis by VEGF inhibitorsmay be an important factor (Dhaun and Webb, 2010; Syrigos
et al., 2011; Ng et al., 2007). Although plasma clearance of
[11C]docetaxel decreased slightly after bevacizumab administra-
tion, signifying prolonged duration of [11C]docetaxel exposure,
this decrease in clearance appeared to be too limited to result
in an overall increase in [11C]docetaxel uptake, that is, retention
index, by tumors.
Bevacizumab was selected to investigate the effects of anti-
angiogenic agents, as it is the most selective inhibitor of VEGF
signaling among presently approved anti-angiogenic drugs,
and it does not have multiple targets like most tyrosine kinase
inhibitors. In addition, the long terminal half-life of 17–21 days
(Ferrara et al., 2004) enables sequential measurements after
a single administration of bevacizumab. The study was conduct-
ed in patients with advanced-stage NSCLC, as noninvasive
PET-CT measurements using [15O]H2O and [
11C]docetaxel
were previously found to be feasible in this patient group (Van
der Veldt et al., 2011). As a result, [11C]docetaxel measurements
could be repeated in individual patients who acted as their own
control. Although both docetaxel and bevacizumab are active
agents for the treatment of advanced lung cancer (Sandler
et al., 2006; Kudoh et al., 2006), single-agent bevacizumab is
not considered effective for the treatment of NSCLC patients.
Consequently, ethically it was not acceptable to prolong the
study with PET measurements at later time points. In addition,
the localization of the lung tumors did not enable invasive
measurements of interstitial fluid pressure (Curti et al., 1993) or
sequential biopsies for additional histopathological analyses.
Furthermore, use of tracer amounts of docetaxel (microdoses)
Figure 5. Plasma Clearance of [11C]docetaxel at
Baseline and after Administration of Bevacizumab
(A) Example of plasma activity curves of [11C]docetaxel in
a patient at baseline and after 5 hr and 4 days following
bevacizumab administration. Plasma activity curves are
divided by injected dose (ID).
(B) Plasma clearance of [11C]docetaxel in 10 NSCLC
patients at baseline and after administration of bev-
acizumab.
Horizontal bars represent median values.
*p values < 0.05.
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able that the effects of bevacizumab on [11C]docetaxel delivery
in tumors may not hold true for pharmacological drug concentra-
tions. However, use of repeated therapeutic doses mixed with
the radiolabeled drug, instead of microdoses, will obscure
bevacizumab-induced effects, as cytotoxic drugs themselves
also affect both tumor perfusion (Dunnwald et al., 2008) and
interstitial fluid pressure (Griffon-Etienne et al., 1999) and may
modulate the specific targets of the drug under study (Shalli
et al., 2005). In a separate study, in which [11C]docetaxel was
given at tracer concentrations and during infusion of a thera-
peutic dose, albeit was possible to predict tumor uptake of
(therapeutic) docetaxel from the tumor kinetics of (tracer)
[11C]docetaxel (data not shown), indicating that the present
bevacizumab-induced decrease in [11C]docetaxel uptake in
tumors is likely to represent changes in tumor uptake of thera-
peutic doses of docetaxel.
The results of the present study pose a number of important
issues relevant to anti-angiogenic drugs administered in combi-
nation with other anticancer drugs. In human tumors, bevacizu-
mab induced a rapid decrease in perfusion and [11C]docetaxel
uptake. It is conceivable that other inhibitors of the VEGF
signaling pathways may produce similar effects. In addition, it
is likely that these effectsmay persist during continued treatment
with these drugs. Therefore, administration of anti-angiogenic
drugs can be considered after administration of the other anti-
cancer agents, as the immediate decrease in tumor perfusion
should decrease clearance of drugs from tumors. Hence,
preclinical studies are warranted to investigate this concept for
scheduling of anticancer drugs. To improve scheduling of
combination therapy, other potential mechanisms need to be
investigated to understand the synergistic effects with anti-
angiogenic drugs. In this regard, it is important to explore the
effects of anti-angiogenic drugs on proliferative activity of tumor
cells (Ortholan et al., 2010) and their environment, such as
mobilization of bone marrow-derived circulating endothelial
progenitor cells (Shaked et al., 2008) and acute release of
cytokines from the tumor microenvironment (Gilbert and He-
mann, 2010).
The results of the present study may explain why several
clinical trials have failed to show the additional value of anti-
angiogenic drugs in specific populations of cancer patients.
Clearly, more clinical studies are needed to assess whether
administration schedules affect response and outcome of com-
bination strategies. To this end, the optimal design to prove
clinical relevance of drug scheduling would be a randomized
controlled trial in which cancer patients are randomized to
different administration schedules.In conclusion, the results of this human study indicate a rapid
and significant reduction in perfusion and [11C]docetaxel uptake
in NSCLC after administration of bevacizumab. The clinical rele-
vance of these findings is notable, as the present study did not
provide evidence for a substantial improvement in drug delivery
to tumors but rather showed the opposite effect. These findings
highlight the importance of drug scheduling and advocate further
studies to optimize scheduling of anti-angiogenic drugs.
EXPERIMENTAL PROCEDURES
Patient Selection
Between October 2009 and September 2010, ten patients (six men and four
women; median age 58 years; range, 47–70 years) with advanced-stage
NSCLC were prospectively enrolled. Patients participated in this study prior
to their scheduled therapy. The study was approved by the Medical Ethics
Review Committee of the VU University Medical Center, Amsterdam. All
patients signed a protocol-specific informed consent form prior to study
enrollment.
Inclusion criteria were the following: age R18 years; a malignant lesion
R1.5 cm in diameter within the chest; life expectancy of at least 12 weeks;
Eastern Cooperative OncologyGroup performance status <3;R4weeks since
any prior surgery or radiotherapy; no previous acute toxicities (>1) in accor-
dance with Common Terminology Criteria for Adverse Events v3.0 (CTCAE);
adequate organ function [hemoglobin R6.0 mmol∙l1; absolute neutrophil
countR1.53 109/l; absolute platelet count >1003 109/l; total serum bilirubin
%1.5 upper limit of normal (ULN); aspartate aminotransferase and alanine
aminotransferase%2.5 x ULN (in case of liver metastases% 5 x ULN); alkaline
phosphatase%2.5 x ULN; serum creatinine%1.5 ULN or creatinine clearance
R60 ml∙min1; normal serum calcium; urine dipstick for proteinuria <2+]; and
use of effective contraception.
Exclusion criteria were the following: squamous lung cancer; history of R
grade 2 hemoptysis; cavitary lesion; tumor invading major blood vessels;
newly diagnosed and untreated central nervous system metastases; any
unstable systemic disease (including but not limited to clinically significant
cardiovascular disease and uncontrolled hypertension); major surgery or
significant traumatic injury <28 days before study entry; prior treatment with
taxanes or bevacizumab; concurrent treatment with other anticancer agents
or experimental drugs; use of inhibitors or substrates of the efflux transporter
ABCB1; serious nonhealing wound or ulcer; a history of documented hemor-
rhagic diathesis or coagulopathy; therapeutic anticoagulation; regular use of
aspirin (>325 mg per day); planned radiotherapy or major surgery; pregnancy
or lactation; metal implants (e.g., pacemakers); and claustrophobia.
Study Design
Patients received a single infusion of bevacizumab (15 mg$kg1, infused over
90 min). In the week prior to this infusion, patients underwent a dynamic PET-
CT study with both [15O]H2O and [
11C]docetaxel. At 5 hr and 4 days after infu-
sion of bevacizumab, the PET-CT protocol was repeated. In addition, 2 hr after
infusion of bevacizumab, patients underwent an additional dynamic PET-CT
scan with [15O]H2O. Sequential scans were possible because of the short
half-lives of oxygen-15 and carbon-11, which are 2.0 and 20.3 min, respec-
tively. Initially, the last time point for PET measurements was set at day 7.
However, recruitment of patients seemed difficult, as patients were not willingCancer Cell 21, 82–91, January 17, 2012 ª2012 Elsevier Inc. 87
Figure 6. Perfusion and [11C]docetaxel Uptake in
the Vertebral Body, which Represents Bone
Marrow, in Ten Individual Patients at Baseline
and after Administration of Bevacizumab
Horizontal bars represent median values.
(A) Perfusion (F).
(B) Net rate of influx (Ki) of [
11C]docetaxel.
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Effects of Bevacizumab on Delivery of Chemotherapyto postpone their planned chemotherapy for more than a few days. Hence, the
protocol was amended and the last time point was set at day 4. Adverse events
were graded in accordance with CTCAE v3.0. After the last PET-CT study,
patients started with their scheduled therapy. In accordance with the guide-
lines of the Medical Ethics Review Committee of the VU University Medical
Center, the total radiation burden of the study was estimated at <10 mSv.
As efficacy was not an endpoint of the present study, response evaluation
and data collection for survival were not performed.
Synthesis of Radiopharmaceuticals
The radiosyntheses of [15O]H2O and [
11C]docetaxel were performed in accor-
dance with good manufacturing practice (GMP) standards (Jackson et al.,
1993; van Tilburg et al., 2004 and 2008). Docetaxel, obtained from Green
PlantChem Company (Hangzhou, China), was chemically modified and used
as precursor in the synthesis of [11C]docetaxel. 11C-labeled docetaxel was ob-
tained with an isolated decay-corrected radiochemical yield of 10 ± 2% and
a radiochemical purity of >98%. [11C]docetaxel has an identical molecular
structure as the drug docetaxel. The identity of [11C]docetaxel was confirmed
by comparison of retention times on high-performance liquid chromatography
with authentic docetaxel.
Scanning Protocol
Imaging studies were performed on a state-of-the-art three-dimensional (3D)
PET-CT scanner (Gemini TF-64, Philips Medical Systems, Best, The Nether-
lands; Surti et al., 2007). This scanner has an axial field of view of 18 cm,
divided into 45 contiguous planes. All patients underwent PET-CT scans
with [15O]H2O and [
11C]docetaxel at baseline and at day 4. Nine patients
underwent a [15O]H2O PET-CT scan at 2 hr and eight patients underwent
combined [15O]H2O and [
11C]docetaxel PET-CT scans at 5 hr, whereas one
patient underwent a single [11C]docetaxel PET-CT scan at 5 hr. The median
times from the end of the bevacizumab infusion to the first, second, and third
scan sessions were 1.9 hr (range, 1.4–2.3 hr), 5.6 hr (range, 4.9–8.6 hr), and
4 days (range, 3–5 days). Sudden technical difficulties, clinical problems,
and logistic issues were the reasons for missing scans and different time
intervals.
Until 3 hr prior to scanning, food and drinks were allowed. On the day of
a PET study, patients were asked to consume similar meals prior to scanning.
All patients received two venous catheters, one for tracer injection and the
other for blood sampling. Patients were positioned supine on the scanner
bed, with both tumor and aortic arch located inside the axial field of view of
the scanner. Elastic body-restraining bandages were used to minimize move-
ment during scanning.
A 10 min dynamic scan was started simultaneously with an intravenous
injection of 370 MBq [15O]H2O (5 ml at a rate of 0.8 ml$s
1, followed by
a 35 ml saline flush at a rate of 2 ml$s1). Thereafter, a 50 mAs low-dose CT
scan was performed for attenuation correction purposes. At least 20 min after
administration of [15O]H2O, a 60min dynamic scan was started simultaneously
with an intravenous injection of [11C]docetaxel (dissolved in a maximum
volume of 12 ml saline, infused at a rate of 0.8 ml$s1, and followed by a 35 ml
saline flush at a rate of 2 ml$s1). The median injected dose of [11C]docetaxel
was 344 MBq (range, 122–388 MBq) with a median specific activity of 3.2
GBq$mmol1 (range; 1.0–25.8 GBq$mmol1). During PET scanning, blood
pressure was monitored with a Dinamap (Dash 4000, GE Medical Systems
Information Technologies, Inc., Milwaukee, Wisconsin).88 Cancer Cell 21, 82–91, January 17, 2012 ª2012 Elsevier Inc.Data were normalized and all appropriate corrections
for dead time, decay, randoms, scatter, and attenuation
were applied. Using the 3D row actionmaximum likelihood
reconstruction algorithm, [15O]H2O and [
11C]docetaxelscans were reconstructed into 26 (1x10, 8x5, 4x10, 2x15, 3x20, 2x30, and
6x60 s) and 36 (1x10, 8x5, 4x10, 2x15, 3x20, 2x30, 6x60, 4x150, 4x300, and
2x600 s) frames, respectively.
Blood Sampling
Sequential blood samples were collected in ACD vacutainers (8.5 ml, Becton
Dickinson, Heidelberg, Germany; Cat. No. 364606) at baseline, and at 3 hr
and 4 days after the end of the bevacizumab infusion. Prior to each sample,
3 ml–5 ml blood was discarded and the line was flushed with 2 ml saline after
each sample. After collection, the blood samples were centrifuged immedi-
ately to obtain platelet-rich plasma (15 min; 20C; 156 x g; N = 7 patients).
Platelet-rich plasma was further centrifuged to obtain platelet-poor plasma
(15 min; 20C; 330 x g; N = 3 patients). Thereafter, plasma was stored at
20C until analysis. Concentrations of VEGF (pg∙ml1) were assessed in
duplicate using a Quantikine enzyme-linked immunosorbent assay (ELISA)
kit (R&DSystems,Minneapolis, Minnesota). Vascular endothelial growth factor
concentrations in platelet-rich plasma were corrected for platelet count and
were expressed in pg$ml1 per 200,000 platelets$ml1.
After intravenous injection of [11C]docetaxel, 10 ml discrete venous samples
were collected manually at 2.5, 5, 10, 15, 20, 30, 40, and 60 min post-injection.
Blood samples were analyzed for radioactivity concentrations in blood and
plasma. Whole blood (0.5 ml) was weighted in duplicate and 0.05 ml 10%
Triton X-100 solution was added. After centrifuging the remaining whole blood
(5 min; room temperature; 4000 rpm), plasma was harvested and 0.5 ml
plasma was weighted in duplicate, again adding 0.05 ml 10% Triton X-100
solution. A well-counter, cross-calibrated against the PET scanner, was
used to determine activity concentrations. Samples were not analyzed for
radiolabeledmetabolites, as these were not detected previously (Van der Veldt
et al., 2011).
Input Functions
Kinetic analyses of data were performed using dedicated programs written
within the software environment Matlab (The MathWorks Inc., Natick, Massa-
chusetts). The ascending aorta in the [15O]H2O and [
11C]docetaxel images
was used to generate noninvasive image-derived input functions (IDIF), as
validated previously (van der Veldt et al., 2010a and 2011). Volumes of
interest (VOI) of 1 cm diameter were drawn over the ascending aorta in
approximately ten consecutive image planes of the frame in which the first
pass of the bolus was best visualized. Projection of these VOIs onto all image
frames yielded the arterial time-activity curve (TAC) CA(t). A similar approach
was used for the pulmonary artery in approximately five consecutive planes,
thereby providing a TAC for the pulmonary circulation CV(t) (van der Veldt
et al., 2010a). The [11C]docetaxel plasma IDIF was obtained by multiplying
CA(t) with a sigmoid function (Gunn et al., 1998), which was obtained by
fitting the plasma/whole blood ratios derived from the venous samples. As
the rapid [11C]docetaxel clearance precludes reliable input functions at later
time points, the generation of input functions of [11C]docetaxel was limited to
the first 10 min of data (Van der Veldt et al., 2011).
Analysis of Perfusion and [11C]docetaxel Kinetics in Tumors
Scans were anonymized and randomly presented to an experienced observer
(I.B.) who was blinded to patients’ history and outcome. To delineate compa-
rable tumor VOIs, this observer analyzed all scans from one patient in the same
session. Low-dose CT images were converted to ECAT 7 format. Thereafter,
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software package (CTI/Siemens, Knoxville, Tennessee). Next, VOIs were
projected onto the dynamic images of the corresponding [15O]H2O and
[11C]docetaxel scans, thereby generating tumor TACs for [15O]H2O and
[11C]docetaxel, respectively.
The standard single-tissue compartment model was used to derive tumor
perfusion from [15O]H2O kinetics (Hermansen et al., 1998; van der Veldt
et al., 2010a). Using nonlinear regression, [15O]H2O tumor TACs were fitted
to the single-tissue compartment model using IDIF as arterial input function
(van der Veldt et al., 2010a). The correction for pulmonary circulation blood
volume was included, as it improves the quality of the fits without affecting
tumor perfusion values. Using this approach, the absolute test-retest vari-
ability of tumor perfusion is 0.03 ml$cm3$min1 (van der Veldt et al., 2010a).
The kinetics of [11C]docetaxel in tumors was described by a two-tissue irre-
versible compartment model, linearized using the Patlak method (Patlak et al.,
1983). When applying the Patlak method to the first 10 min of dynamic PET
data with the starting time at 2 min, the Ki of [
11C]docetaxel has an absolute
test-retest variability of 0.003 ml$cm3$min1 (van der Veldt et al., 2011). In
addition, the retention index of [11C]docetaxel in tumor tissue was calculated
by dividing the measured radioactivity concentration at 10 min post-injection
by the integral of the plasma curve up to this time.
To analyze heterogeneity of tumor perfusion at the voxel level, parametric
perfusion images were generated (van der Veldt et al., 2010a). Hence, IDIFs
and a basis function implementation of the standard single-tissue compart-
ment model were applied (Boellaard et al., 2005; Lodge et al., 2000; Watabe
et al., 2005). Fifty logarithmically spaced, precomputed basis functions with
F/VT values, ranging from 0.1 to 2.0 min
1 were used and parametric perfusion
images were postsmoothed with a Gaussian filter of 10 mm full width at half
maximum. Then, VOIs previously defined on the low-dose CT scans were
projected onto the parametric perfusion images. Next, voxel intensity histo-
grams were generated for the whole VOI, its center and its rim. A voxel was
considered to be part of the rim if at least one of the voxels in its 3D six-con-
nected neighborhood was outside the defined VOI. In accordance with this
method, the median baseline volume of the whole tumor VOI was 13.3 cm3
(range, 1.7–278.5 cm3) with center and rim accounting for median volumes
of 2.5 cm3 (range, 0.1–183.8 cm3) and 9.1 cm3 (range, 1.5–81.3 cm3),
respectively. Similarly, voxel intensity histograms were generated for the Ki
of [11C]docetaxel, applying the Patlak method on a voxel basis. The voxel
intensity histograms were used to characterize tumor heterogeneity of
perfusion and [11C]docetaxel uptake, analyzing the following parameters:
percentage of voxels, mean value, standard deviation, median value, minimal
value, maximal value, kurtosis, and skewness of the distribution. More homog-
enous distributions are characterized by lower standard deviations and higher
kurtosis (more peaked distribution) of corresponding histograms.
Cardiac Output
Using dynamic [15O]H2O PET data, the cardiac output can be estimated by the







where the injected radioactivity (ID) of [15O]H2O is divided by the area under
the curve of the blood activity in the pulmonary artery (CV) multiplied by the
duration of the first pass of the bolus. The TAC of the pulmonary artery was
fitted with a linear upslope and followed by an exponential downslope, which
was extrapolated to remove contamination of recirculating radioactivity.
Microcirculation in the Skin
In eight patients, microcirculation in the skin was investigated. At baseline,
3 hr and 4 days, nailfold capillaries in the dorsal skin of the third finger were
visualized using a capillary microscope (Serne´ et al., 2001). Capillary density
was defined as the number of erythrocyte-perfused capillaries$mm2. First,
baseline capillary density was recorded for 2 min. Thereafter, venous
occlusion was applied to expose a maximal number of perfused capillaries.
To this end, a digital cuff was inflated to 60 mmHg for 60 s. Recordings
were presented randomly and in a blind fashion to an experienced investigator(M.P.d.B.), who counted number of capillaries off-line from a videotape. Using
the same visual fields as used during baseline measurements, peak capillary
density during venous congestion was counted in the 60 s recordings. Day-
to-day variation of baseline capillary density and peak capillary density during
venous congestion were 2.3% ± 1.8% (Serne´ et al., 2002) and 9.5 ± 7.1%
(Serne´ et al., 2001), respectively.
Muscle Perfusion
On the low-dose CT scans, VOIs (diameter, 1 cm) were drawn over the erector
spinae muscle in five consecutive image planes. Projection of these muscle
VOIs onto the dynamic images of the corresponding [15O]H2O scan yielded
a muscle TAC for [15O]H2O. The standard single-tissue compartment model
was used to derive muscle perfusion (Hermansen et al., 1998) but without






where CT(t) is the total measured tissue signal in tumor as function of time, F is
perfusion, VA is arterial blood volume, and VT is the volume of distribution
or partition coefficient of water. To evaluate [11C]docetaxel kinetics in
normal tissue, muscle VOIs were also projected onto the corresponding
[11C]docetaxel image and those TACs were analyzed using the Patlak method
(Patlak et al., 1983).
[11C]docetaxel Clearance
To determine influence of bevacizumab on blood kinetics of [11C]docetaxel,




where the injected dose (ID) of [11C]docetaxel is divided by the integral of the
plasma (CP) TAC multiplied by the body surface area.
Thyroid Perfusion
In those cases in which the thyroid gland was in the field of view, additional
parametric perfusion images were generated, using 50 precomputed basis
functions with F/VT values, ranging from 0.1 to 15 min
1 and postsmoothing
with a Gaussian filter of 10 mm in full width at half maximum. Then, the thyroid
gland could be delineated on parametric perfusion images applying a semi-
automatic threshold technique (50% of the maximum voxel value with correc-
tion for local background; van der Veldt et al., 2010a). Thereafter, these VOIs
were projected onto the dynamic [15O]H2O images. Again, the standard
single-tissue compartment model (Equation 2) was applied to calculate
perfusion.
Perfusion and [11C]docetaxel Kinetics in Bone Marrow
Perfusion and [11C]docetaxel uptake were determined in the vertebral body,
representing active bone marrow. From the level of the main carina to ten
image planes downwards, VOIs (diameter, 1.5 cm) were defined in the verte-
bral body on low-dose CT scans. These VOIs were projected onto dynamic
images of the [15O]H2O and [
11C]docetaxel scans, generating corresponding
TACs.
Equation 2 was applied to calculate vertebral body perfusion, whereas the
Patlak method (Patlak et al., 1983) was applied to determine [11C]docetaxel
uptake.
Statistics
Statistical analysis was performed using SPSS software (SPSS for Windows
16.0, SPSS, Inc., Chicago, IL). Correlations were explored using the Spear-
man’s correlation coefficient. The Mann-Whitney test was used to compare
between groups. The Wilcoxon signed-rank test was used to compare
variables at 2 hr, 3 hr, 5 hr, and 4 days after bevacizumab administration
with baseline values. A two-tailed probability value of p value < 0.05 was
considered significant.
ACKNOWLEDGMENTS
The authors would like to thank all patients who participated in this study.
In addition, the authors would like to thank Suzette van Balen, AminaCancer Cell 21, 82–91, January 17, 2012 ª2012 Elsevier Inc. 89
Cancer Cell
Effects of Bevacizumab on Delivery of ChemotherapyElouahmani, Judith van Es, Robin Hemminga, Femke Jongsma, Nghi Pham,
Nasserah Sais, and Jeroen Wilhelmus for scanning the patients, Emile
Comans, Otto Hoekstra, Daniela Oprea-Lager, Pieter Raijmakers, Nafees
Rizvi, Natasja Kok, Ilona Pomstra, Atie van Wijk, Sabri Duzenli, Martijn
Groenendijk, Esther Nossent, Arifa Pasic, Suzy Samii, Serge van Wolferen,
and Jennifer Benit for help with logistical planning and patient care, Ronald
Boellaard, Dennis Boersma, Marc Huisman, Arthur van Lingen, and Maqsood
Yaqub for technical assistance; Peter van de Ven for statistical advice; Bart
Kuenen for help with the design of the study; Martien Mooijer, Anneloes
Rijnders, and Dennis Laan for production of [11C]docetaxel; Henk Dekker for
help with the analyses of VEGF levels; and Marissa Rongen, Robert Schuit,
and Kevin Takkenkamp for the production of [15O]H2O and the analysis of
blood samples. This work was supported by a grant of the Cancer Center
Amsterdam. This study was presented in part at the 2011 ASCO Annual
Meeting, Chicago, IL, June 3–7, 2011, #3059; and at the 14th World Confer-
ence on Lung Cancer, Amsterdam, The Netherlands, July 3–7, 2011, #O18.02.
Received: July 23, 2011
Revised: November 2, 2011
Accepted: November 29, 2011
Published: January 17, 2012REFERENCES
Batchelor, T.T., Sorensen, A.G., di Tomaso, E., Zhang, W.T., Duda, D.G.,
Cohen, K.S., Kozak, K.R., Cahill, D.P., Chen, P.J., Zhu, M., et al. (2007).
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor
vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11,
83–95.
Boellaard, R., Knaapen, P., Rijbroek, A., Luurtsema, G.J., and Lammertsma,
A.A. (2005). Evaluation of basis function and linear least squares methods
for generating parametric blood flow images using 15O-water and Positron
Emission Tomography. Mol. Imaging Biol. 7, 273–285.
Carmeliet, P. (2000). Mechanisms of angiogenesis and arteriogenesis. Nat.
Med. 6, 389–395.
Chen, H.X., and Cleck, J.N. (2009). Adverse effects of anticancer agents that
target the VEGF pathway. Nat. Rev. Clin. Oncol. 6, 465–477.
Cobleigh, M.A., Langmuir, V.K., Sledge, G.W., Miller, K.D., Haney, L., Novotny,
W.F., Reimann, J.D., and Vassel, A. (2003). A phase I/II dose-escalation trial of
bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 30
(Suppl 16 ), 117–124.
Curti, B.D., Urba, W.J., Alvord, W.G., Janik, J.E., Smith, J.W., 2nd, Madara, K.,
and Longo, D.L. (1993). Interstitial pressure of subcutaneous nodules in mela-
noma and lymphoma patients: changes during treatment. Cancer Res.
(Suppl ). 53, 2204–2207.
Dhaun, N., and Webb, D.J. (2010). Receptor tyrosine kinase inhibition, hyper-
tension, and proteinuria: is endothelin the smoking gun? Hypertension 56,
575–577.
Dunnwald, L.K., Gralow, J.R., Ellis, G.K., Livingston, R.B., Linden, H.M.,
Specht, J.M., Doot, R.K., Lawton, T.J., Barlow, W.E., Kurland, B.F., et al.
(2008). Tumor metabolism and blood flow changes by positron emission
tomography: relation to survival in patients treated with neoadjuvant chemo-
therapy for locally advanced breast cancer. J. Clin. Oncol. 26, 4449–4457.
Ferrara, N., and Kerbel, R.S. (2005). Angiogenesis as a therapeutic target.
Nature 438, 967–974.
Ferrara, N., Gerber, H.P., and LeCouter, J. (2003). The biology of VEGF and its
receptors. Nat. Med. 9, 669–676.
Ferrara, N., Hillan, K.J., Gerber, H.P., and Novotny, W. (2004). Discovery and
development of bevacizumab, an anti-VEGF antibody for treating cancer.
Nat. Rev. Drug Discov. 3, 391–400.
Gambhir, S.S. (2002). Molecular imaging of cancer with positron emission
tomography. Nat. Rev. Cancer 2, 683–693.
Gilbert, L.A., and Hemann, M.T. (2010). DNA damage-mediated induction of
a chemoresistant niche. Cell 143, 355–366.90 Cancer Cell 21, 82–91, January 17, 2012 ª2012 Elsevier Inc.Griffon-Etienne, G.E., Boucher, Y., Brekken, C., Suit, H.D., and Jain, R.K.
(1999). Taxane-induced apoptosis decompresses blood vessels and lowers
interstitial fluid pressure in solid tumors: clinical implications. Cancer Res.
59, 3776–3782.
Gunn, R.N., Sargent, P.A., Bench, C.J., Rabiner, E.A., Osman, S., Pike, V.W.,
Hume, S.P., Grasby, P.M., and Lammertsma, A.A. (1998). Tracer kinetic
modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for
PET. Neuroimage 8, 426–440.
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100,
57–70.
Hermansen, F., Rosen, S.D., Fath-Ordoubadi, F., Kooner, J.S., Clark, J.C.,
Camici, P.G., and Lammertsma, A.A. (1998). Measurement of myocardial
blood flow with oxygen-15 labelled water: comparison of different administra-
tion protocols. Eur. J. Nucl. Med. 25, 751–759.
Hoekstra, C.J., Stroobants, S.G., Hoekstra, O.S., Smit, E.F., Vansteenkiste,
J.F., and Lammertsma, A.A. (2002). Measurement of perfusion in stage
IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission
tomography. Clin. Cancer Res. 8, 2109–2115.
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J.,
Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004).
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic
colorectal cancer. N. Engl. J. Med. 350, 2335–2342.
Jackson, J.R., Dembowski, B.S., Ehrenkaufer, R.L., McIntyre, E., and Reivich,
M. (1993). [15O]H2O, [15O]O2 and [15O]CO gas production, monitoring and
quality control system. Appl. Radiat. Isot. 44, 631–634.
Jain, R.K. (2001). Normalizing tumor vasculature with anti-angiogenic therapy:
a new paradigm for combination therapy. Nat. Med. 7, 987–989.
Jain, R.K. (2005). Normalization of tumor vasculature: an emerging concept in
antiangiogenic therapy. Science 307, 58–62.
Kamba, T., Tam, B.Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso,
M.R., Norberg, S.M., O’Brien, S.M., Davis, R.B., Gowen, L.C., et al. (2006).
VEGF-dependent plasticity of fenestrated capillaries in the normal adult
microvasculature. Am. J. Physiol. Heart Circ. Physiol. 290, H560–H576.
Knaapen, P., Lubberink, M., Rijzewijk, L.J., van der Meer, R.W., Unger, M.,
Germans, T., Bax, J.J., Smit, J.W., Lamb, H.J., van Rossum, A.C., et al.
(2008). Stroke volume measurements with first-pass dynamic positron emis-
sion tomography: comparison with cardiovascular magnetic resonance.
J. Nucl. Cardiol. 15, 218–224.
Kudoh, S., Takeda, K., Nakagawa, K., Takada, M., Katakami, N., Matsui, K.,
Shinkai, T., Sawa, T., Goto, I., Semba, H., et al. (2006). Phase III study of
docetaxel compared with vinorelbine in elderly patients with advanced non-
small-cell lung cancer: results of the West Japan Thoracic Oncology Group
Trial (WJTOG 9904). J. Clin. Oncol. 24, 3657–3663.
Lodge, M.A., Carson, R.E., Carrasquillo, J.A., Whatley, M., Libutti, S.K., and
Bacharach, S.L. (2000). Parametric images of blood flow in oncology PET
studies using [15O]water. J. Nucl. Med. 41, 1784–1792.
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E.A.,
Shenkier, T., Cella, D., and Davidson, N.E. (2007). Paclitaxel plus bevacizumab
versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357,
2666–2676.
Mourad, J.J., desGuetz, G., Debbabi, H., and Levy, B.I. (2008). Blood pressure
rise following angiogenesis inhibition by bevacizumab. A crucial role for micro-
circulation. Ann. Oncol. 19, 927–934.
Ng, Q.S., Goh, V., Milner, J., Stratford, M.R., Folkes, L.K., Tozer, G.M.,
Saunders, M.I., and Hoskin, P.J. (2007). Effect of nitric-oxide synthesis on
tumour blood volume and vascular activity: a phase I study. Lancet Oncol.
8, 111–118.
Ortholan, C., Durivault, J., Hannoun-Levi, J.M., Guyot, M., Bourcier, C.,
Ambrosetti, D., Safe, S., and Page`s, G. (2010). Bevacizumab/docetaxel asso-
ciation is more efficient than docetaxel alone in reducing breast and prostate
cancer cell growth: a new paradigm for understanding the therapeutic effect of
combined treatment. Eur. J. Cancer 46, 3022–3036.
Cancer Cell
Effects of Bevacizumab on Delivery of ChemotherapyPatlak, C.S., Blasberg, R.G., and Fenstermacher, J.D. (1983). Graphical eval-
uation of blood-to-brain transfer constants from multiple-time uptake data.
J. Cereb. Blood Flow Metab. 3, 1–7.
Reese, D., Fratesi, P., Corry, M., Novotny, W., Holmgren, E., and Small, E.
(2001). A phase II trial of humanized anti-vascular endothelial growth factor
antibody for the treatment of androgen-independent prostate cancer. The
Prostate J. 3, 65–70.
Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A.,
Lilenbaum, R., and Johnson, D.H. (2006). Paclitaxel-carboplatin alone or
with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355,
2542–2550.
Serne´, E.H., Gans, R.O., ter Maaten, J.C., Tangelder, G.J., Donker, A.J., and
Stehouwer, C.D. (2001). Impaired skin capillary recruitment in essential hyper-
tension is caused by both functional and structural capillary rarefaction.
Hypertension 38, 238–242.
Serne´, E.H., IJzerman, R.G., Gans, R.O., Nijveldt, R., De Vries, G., Evertz, R.,
Donker, A.J., and Stehouwer, C.D. (2002). Direct evidence for insulin-induced
capillary recruitment in skin of healthy subjects during physiological hyperinsu-
linemia. Diabetes 51, 1515–1522.
Shaked, Y., Henke, E., Roodhart, J.M., Mancuso, P., Langenberg, M.H.,
Colleoni, M., Daenen, L.G., Man, S., Xu, P., Emmenegger, U., et al. (2008).
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization:
implications for antiangiogenic drugs as chemosensitizing agents. Cancer
Cell 14, 263–273.
Shalli, K., Brown, I., Heys, S.D., and Schofield, A.C. (2005). Alterations of
beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J.
19, 1299–1301.
Surti, S., Kuhn, A., Werner, M.E., Perkins, A.E., Kolthammer, J., and Karp, J.S.
(2007). Performance of Philips Gemini TF PET/CT scanner with special consid-
eration for its time-of-flight imaging capabilities. J. Nucl. Med. 48, 471–480.
Syrigos, K.N., Karapanagiotou, E., Boura, P., Manegold, C., and Harrington, K.
(2011). Bevacizumab-induced hypertension: pathogenesis and management.
BioDrugs 25, 159–169.
van der Veldt, A.A., Hendrikse, N.H., Harms, H.J., Comans, E.F., Postmus,
P.E., Smit, E.F., Lammertsma, A.A., and Lubberink, M. (2010a). Quantitativeparametric perfusion images using 15O-labeled water and a clinical PET/CT
scanner: test-retest variability in lung cancer. J. Nucl. Med. 51, 1684–1690.
Van der Veldt, A.A., Hendrikse, N.H., Smit, E.F., Mooijer, M.P., Rijnders, A.Y.,
Gerritsen, W.R., van der Hoeven, J.J., Windhorst, A.D., Lammertsma, A.A.,
and Lubberink, M. (2010b). Biodistribution and radiation dosimetry of 11C-
labelled docetaxel in cancer patients. Eur. J. Nucl. Med. Mol. Imaging 37,
1950–1958.
Van der Veldt, A.A., Lubberink, M., Greuter, H.N., Comans, E.F., Herder, G.J.,
Yaqub, M., Schuit, R.C., Van Lingen, A., Rizvi, S.N., Mooijer, M.P., et al. (2011).
Absolute quantification of [11C]docetaxel kinetics in lung cancer patients
using positron emission tomography. Clin. Cancer Res. 15, 4814–4824.
van Tilburg, E.W., Franssen, E.J., Van der Hoeven, J.J., Van der Meij, M.,
Elshove, D., Lammertsma, A.A., and Windhorst, A.D. (2004). Radiosynthesis
of [11C]docetaxel. J. Labelled Comp. Rad. 47, 763–777.
van Tilburg, E.W., Mooijer, M.P., Brinkhorst, J., van der Meij, M., and
Windhorst, A.D. (2008). Improved and semi-automated GMP-compliant radio-
synthesis of [11C]docetaxel. Appl. Radiat. Isot. 66, 1414–1418.
Verheul, H.M., Hoekman, K., Luykx-de Bakker, S., Eekman, C.A., Folman,
C.C., Broxterman, H.J., and Pinedo, H.M. (1997). Platelet: transporter of
vascular endothelial growth factor. Clin. Cancer Res. 3, 2187–2190.
Watabe, H., Jino, H., Kawachi, N., Teramoto, N., Hayashi, T., Ohta, Y., and
Iida, H. (2005). Parametric imaging of myocardial blood flow with 15O-water
and PET using the basis function method. J. Nucl. Med. 46, 1219–1224.
Willett, C.G., Boucher, Y., di Tomaso, E., Duda, D.G., Munn, L.L., Tong, R.T.,
Chung, D.C., Sahani, D.V., Kalva, S.P., Kozin, S.V., et al. (2004). Direct
evidence that the VEGF-specific antibody bevacizumab has antivascular
effects in human rectal cancer. Nat. Med. 10, 145–147.
Wilson, C.B., Lammertsma, A.A., McKenzie, C.G., Sikora, K., and Jones, T.
(1992). Measurements of blood flow and exchanging water space in breast
tumors using positron emission tomography: a rapid and noninvasive dynamic
method. Cancer Res. 52, 1592–1597.
Yang, J.C., Haworth, L., Sherry, R.M., Hwu, P., Schwartzentruber, D.J.,
Topalian, S.L., Steinberg, S.M., Chen, H.X., and Rosenberg, S.A. (2003). A
randomized trial of bevacizumab, an anti-vascular endothelial growth factor
antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427–434.Cancer Cell 21, 82–91, January 17, 2012 ª2012 Elsevier Inc. 91
